Debt ratio 79.26% (improved from 80.57% at year-end 2025), allowance for doubtful accounts 3.82% – sound financial position
2024-2026 shareholder return policy: utilize ≥50% of separate FCF, target total dividends ≥KRW 30B over 3 years; paid KRW 10.6B in 2024 and KRW 11.0B in 2025 (progress 72.2%)\- Quarterly dividend of KRW 700/sh, year-end dividend of KRW 1,000/sh plus 3% stock dividend maintained; all treasury shares disposed
R&D expenditure KRW 4.9B (1.44% of sales); 34 product launches completed in the period
Key subsidiaries: Dong-A Pharm OP KRW 20.6B (+21.9% YoY), Yongma Logistics revenue KRW 110.6B (+9.6%), Vitagen revenue KRW 18.0B (-5.7%), Dong-A EcoPack OP loss KRW 1.6B (narrower loss)\- Equity-method income from associates (Dong-A ST, ST Pharm, etc.) KRW 5.0B, up from prior quarter
Litigation: 1 case as plaintiff (KRW 0.51B), financial impact unpredictable